Comprehensive Cancer Genomic Profiling Service

ACTOnco®+ : Find the Right Treatment For Your Cancer Patient

Planning treatment strategies through comprehensive genomic profiling for 440 cancer-related genes

The Recommended Choice for Cancer Genomic Profiling

ACTOnco®+ is a next-generation sequencing based assay, sequencing 440 cancer- related genes simultaneously from cancer specimens in our ISO 17025 and CAP accredited lab. This assay is specially designed for patients with all types of solid tumors, providing comprehensive genomic profile and recommendations of targeted drugs well-selected from FDA-approved lists and clinical trials.

Analyzing Cancer Signaling Pathway to Identify All Matching Drugs

Comprehensively identifies genetic alterations of each signaling pathway to evaluate drug options based on upstream and downstream interactions and increase treatment efficacy.

Cancer Signaling Pathway Analysis-Identify more treatment options with pathway integration

In addition to EGFR, its downstream genes and other signaling pathways involve other cancer-related genes. Related target drugs can therefore be selected to treat patients with these mutations, avoiding drug resistance and providing more therapeutic options


Hallmark of ACTOnco®+

  1. Comprehensive Cancer Types

    All Solid Tumors
  2. Suitable for Most Patients

    - Patients newly diagnosed with cancer

    - Patients to be treated with chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy for the first time

    - Patients with recurrence or metastasis

    -Patients with resistance to existing treatment

  3. Comprehensive Report Content

    - Genetic alterations, including BRCA1/2

    - -Therapeutic implications for FDA approved chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy drugs and other drugs used in clinical trials

    - Prediction of immunotherapy response, including MSI status

    - Pharmacogenomics information

Why ACTOnco®+

Can Provide Comprehensive Solutions

  1. Pathway-Based Panel

    Sequencing of 440 cancer-related genes covered most key cancer signaling pathways for targeted therapy
  2. Offering More Drug Options

    Analyzing single nucleotide variation (SNV), small insertion/deletion (InDel) and copy number variation (CNV) to provide more drug options based on pathway analysis
  3. Short Turnaround Time

    Providing professional solutions within 14 calendar days
  4. High Sensitivity

    Using NGS platform for microscale specimens
  5. Pioneering Bioinformatics

    Integrating cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science, and pharmaceutical biology to provide insightful interpretation
  6. Predicting immunotherapy response

    Incorporating mutation burden, immune-related gene information and MSI status for a more accurate immunotherapy recommendation
  7. Pharmacogenetics information

    Responses to treatment may be affected by inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective, while causing less side-effects.


Comprehensive Exon Sequencing

440 Cancer-related genes


> 6800

Additional Assay

Microsatellite instability (MSI) testing

NGS Sequencing Mean Depth

> 800 X

Sample Types


Core needle biopsy

Frozen tissue

Pleural effusion

Ascites samples

Purified DNA

Additional Assay for Lung Cancer

fusion gene detection

( including 72 fusion transcripts )